Protalix BioTherapeutics, Inc.

PLX NYSE SEC CIK 1006281
Follow Protalix BioTherapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $21.9M +22.8% vs same quarter last year
Net income $4M +68.2% vs same quarter last year
EPS, diluted $0.05 +66.7% vs same quarter last year
Operating cash flow $3.9M +204.6% vs same quarter last year
Revenue by quarter
$18.2M
$10.1M
$15.7M
$17.9M
$9.1M
$33.8M
$19.9M
$21.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$100M−$50M$0$50M$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$52.7M−$6.6M
FY24$53.4M$2.9M
FY23$65.5M$8.3M
FY22$47.6M−$14.9M
FY21$38.4M−$27.6M
FY20$62.9M−$6.5M
FY19$54.7M−$18.3M
FY18$34.2M−$26.5M
FY17$21.1M−$83.4M
FY16$9.2M−$29.4M
FY15$4.4M$58M
FY14$3.5M−$29.9M
FY13$0−$27.8M
FY12$34.9M−$11.6M
FY11$8.4M−$36.5M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−1000%0%1000%2000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2548.8%−10.4%−12.5%
FY2454.5%7.3%5.5%
FY2364.9%16%12.7%
FY2258.9%−27.3%−31.3%
FY2157.4%−53.4%−71.9%
FY2082.7%4.3%−10.4%
FY1980.1%−19.6%−33.4%
FY1872.8%−56.4%−77.3%
FY1719%−163.8%−395.9%
FY168.7%−360.5%−319.2%
FY1583.3%−542.4%1329.9%
FY1482.1%−810.6%−849.9%
FY13---
FY1275.4%−34.9%−33.3%
FY1117.2%−435.6%−435.6%
Free cash flowOperating cash flow minus capital expenditure
−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$13.6M
FY24$7.4M
FY23−$2.5M
FY22−$25.6M
FY21−$11.7M
FY20−$26.8M
FY19−$20M
FY18−$8.4M
FY17−$11M
FY16−$32.9M
FY15−$24.7M
FY14−$30.1M
FY13−$32.5M
FY12−$1.4M
FY11−$29.3M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Protalix BioTherapeutics
  • Healthcare median
−1000%0%1000%2000%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearProtalix BioTherapeuticsHealthcare median
FY25−12.5%−30.6%
FY245.5%−47%
FY2312.7%−58%
FY22−31.3%−80.4%
FY21−71.9%−71.8%
FY20−10.4%−62.2%
FY19−33.4%−46.2%
FY18−77.3%−49.6%
FY17−395.9%−45.9%
FY16−319.2%−36%
FY151329.9%−37.8%
FY14−849.9%−35.5%
FY13-−37.1%
FY12−33.3%−29.1%
FY11−435.6%−27.9%